Ashton-Rickardt Philip 4
4 · Sigilon Therapeutics, Inc. · Filed Jan 4, 2022
Insider Transaction Report
Form 4
Ashton-Rickardt Philip
Chief Scientific Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-01-03$3.03/sh+90,000$272,700→ 90,000 totalExercise: $3.03Exp: 2032-01-02→ Common Stock (90,000 underlying)
Footnotes (1)
- [F1]The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 30% on January 3, 2023 and 70% on January 3, 2024.